LGALS3 and cancer: A total of two studies [15,19] (133 patients) were included in the assessment of pre–post galectin-3 levels in relation to cancer-therapy-related cardiotoxicity with an HR of 1.39 (90% CI 0.97, 1.98) (I2: 0%, p = 0.39) (Figure 4).